CHIMERIC THERAPEUTICS

Annual General Meeting

Corporate Update I November 22, 2021

CHIMERIC THERAPEUTICS
CORPORATE SNAPSHOT

- The **ASX leader** in **cell therapy** as the only clinical stage cell therapy company
- Lead asset, **CHM 1101** (CLTX CAR T) **advancing** in a **phase 1 clinical trial with promising early clinical data**
- **CHM 2101** (CDH17 CAR T) **making rapid progress to Phase 1 in 2022**
- **Further advancing pipeline** development with innovative cell therapies
- Industry leading expertise and experience in cell therapy development

Founded in 2020 and listed on the **ASX (CHM)** in **January 2021** with an oversubscribed raise of **$35M**



Market Cap: AUS ~$110M
Shares on Issue: 330 M

Net Cash: AUS $18M (Sept 21)
Board / Mgmt. Ownership: 30%

OUR MISSION

To Bring the Promise of Cell Therapy to Life





"These are patients with an abysmal prognosis, really without hope and now with CAR T therapy we're really able to give them a chance.
This is a revolution. It's a revolution in cancer care. This is the tip of the iceberg,"

Fred Locke, MD
Moffit Cancer Center

Traditional drug development focuses on delaying disease progression- not on a cure.

We believe that novel cellular therapies have the promise to cure cancer.

Our mission is to to bring that promise to life for more patients with cancer.

"With about 6 months to live, I got a call asking if I wanted to join a CAR T clinical trial. ***I believe that call saved my life.***"

Dimas Padilla
Cancer Survivor

CELL THERAPY INVESTMENT LANDSCAPE

Cell therapy is the most active investment sector in biotech today with ~$20B in financing in 2020

The global market for cell therapies is estimated to reach between USD $8-9 billion by 2026

In the past 18-24 months, 16 of the largest pharmaceutical companies have added cell and gene therapy products to their portfolio

ACQUISITIONS

Gilead acquisition of Kite	$11.9B
Celgene acquisition of Juno	$9B
Astellas acquisition of Xyphos	$665M
Kite acquisition of Cell Design Labs	$567M

PARTNERSHIPS

Janssen & Fate	$3B
Kite & Shoreline	$2.3B
Vertex & CRISPR	$900M
Eli Lilly & Precision	$525M
Merck & Artiva	$1.8B
Roche & Adaptimmune	$3B

IPO's

Sana Biotech	$675M
Lyell	$425M
CARsgen	$400M
Instil Bio	$368M
Graphite Bio	$273M
Century Tx	$243M

CHIMERIC PORTFOLIO DEVELOPMENT STRATEGY

Focused on building a diversified cell therapy pipeline with cutting edge innovation



CHIMERIC PIPELINE
2 NOVEL CAR T CELL THERAPIES



- Ongoing phase 1 clinical trial
- 2 additional phase 1 clinical trials planned for 2022
- Development across 7 different types of cancer

WHAT IS CAR T CELL THERAPY?

Cell therapy is **the transfer of live cells into a patient** to treat or cure a disease.

Chimeric **A**ntigen **R**eceptor **T** (CAR T) Cell Therapy is a type of cell therapy that modifies a patient's own immune cells (T-cells) to use directly against their cancer.



A patient's blood is taken, and their T cells are engineered to express a chimeric antigen receptor that recognizes specific structures (antigens) on the surface of cancer cells.



Once the CAR T cells have been infused into a patient, they seek out the antigen targets on cancerous cells. The CAR T cell then binds to the cancerous cell and sends a signal to kill the cancerous cell.

CHM 1101: CHLOROTOXIN (CLTX) CAR T

CHM 1101 (CLTX CAR T) was designed and studied preclinically in **glioblastoma,** one of the most lethal types of cancer.

Patients with glioblastoma have an **expected survival of ~12 months** and only **38% survive more than one year.**

CHM 1101 uniquely uses Chlorotoxin, a peptide derived from deathstalker scorpion venom to target the glioblastoma cells in patients.

In preclinical studies **CHM 1101** was shown to be able to **find, bind and kill glioblastoma cancer cells better than other immunotherapy targets.**



Chimeric holds a global exclusive license to CLTX CAR T.
CLTX CAR T has a long life, composition of matter intellectual property profile expiring 2036.

CHM 1101 (CLTX CAR T) Ongoing Phase 1 Clinical Trial

Advancing Towards Higher Dose Levels

Primary Objective: To assess the safety of CLTX CAR T cells and to determine the maximum tolerated dose schedule and a recommended Phase 2 dosing plan

Phase 1 Clinical Trial Design: 4 dose levels and 2 routes of administration

DOSE LEVEL 1 **COMPLETE**	**DOSE LEVEL 2 IN PROGRESS**	DOSE LEVEL 3	DOSE LEVEL 4
			
Intratumoral Administration	Intratumoral and Intraventricular Administration	Intratumoral and Intraventricular Administration	Intratumoral and Intraventricular Administration
ICT Administration Total dose: 44 X 10^6	ICT & ICV Administration Total dose: 88 X 10^6	ICT & ICV Administration Total dose: 220 X 10^6	ICT & ICV Administration Total dose: 440 X 10^6

Approximately 18 -36 patients with recurrent or progressive GBM over 24 months

CHM 1101 (CLTX CAR T)
Positive Initial Phase 1 Clinical Data

Society for NeuroOncology

Efficacy

Safety

Bioactivity

75% Disease Control Rate (DCR)

CLTX CAR T demonstrated a 75% Disease Control Rate in the 1st dose level

No Dose Limiting Toxicities

CLTX CAR T cells were generally well tolerated with no dose limiting toxicities

Persistence of Cells

CLTX CAR T cells were shown to persist throughout treatment

CHM 1101 (CLTX CAR T)

SNO Presentation Data Update

(Nov 19, 2021)



CHM 1101 (CLTX CAR T) Clinical Development Program

FDA clearance for Chimeric CLTX IND in August 2021
enables accelerated and expanded clinical development in 2022



CHM 2101 (CDH17 CAR T)

PROMISE FOR GASTROINTESTINAL CANCERS

Exclusive Chimeric licensing from the University of Pennsylvania

- Competitive licensing process for the novel 3rd generation CDH17 CAR T from world renowned cell therapy centre

Dramatic Preclinical Efficacy

- Preclinical evidence in neuroendocrine tumours demonstrated safety with complete tumour eradication with no relapse

Phase 1 Clinical Trial Planned for 2022

- Phase 1 basket trial planned in gastrointestinal (GI) cancers; colorectal, pancreatic and gastric cancer and neuroendocrine tumours



CDH17 CAR T

ACCELERATING DEVELOPMENT TOWARDS THE CLINIC

- ✓ **Completed critical first milestone** on path to clinical manufacturing readiness in 2022
- ✓ Hua laboratory at Penn **advancing preclinical validation**

- CDH17 viral vector manufacturing
- CDH17 preclinical data in neuroendocrine (NET) and gastrointestinal tumours (colorectal, pancreatic and gastric)

- CDH17 clinical manufacturing readiness
- CHM IND filing for phase 1 clinical trial
- Phase 1 clinical trial initiation at University of Pennsylvania with expansion to additional clinical sites

CHIMERIC ONGOING PIPELINE DEVELOPMENT

Further pipeline development is a key focus for 2021-2022



CHIMERIC MANAGEMENT TEAM

GLOBAL EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION



Jennifer CHOW
Chief Operating Officer

- KITE PHARMA
  Head of Global Marketing, Commercial Operations and Analytics
- CELGENE
  Global Cell Therapy Commercial Lead

Dr Syed RIZVI
Chief Medical Officer

- LEGEND BIOTECH
  VP, Clinical Development and Medical Affairs
- CELGENE
  Global Cell Therapy Medical Affairs Lead

Dr Eliot BOURK
VP, Business and Corporate Development

- KITE PHARMA
  Head of Early Commercial Development
- CELGENE
  Global Cell Therapy Commercial Strategy and Next Generation Platforms

Dr Li REN
VP, Technical Operations

- BMS
  Global Manufacturing, Cell Therapy Development and Operations
- CELGENE
  CAR T CMC and Technology Development

Development of over

25 CELL THERAPIES

including

4/5 OF THE FDA-APPROVED CAR T CELL THERAPIES

TECARTUS® (brexucabtagene autoleucel) Suspension for IV infusion

YESCARTA® (axicabtagene ciloleucel) Suspension for IV infusion

Breyanzi

Abecma

THE ASX LEADER IN CELL THERAPY

- ✓ **Two novel cell therapy assets from world renowned institutions, University of Pennsylvania and City of Hope**
- ✓ **CLTX CAR T current phase 1 clinical trial advancing in glioblastoma with encouraging early data; 2nd clinical trial planned for 2022 in solid tumours**
- ✓ **CDH17 CAR T broad phase 1 clinical program planned for 2022 in 4 gastrointestinal cancers**
- ✓ **Attractive near term opportunities for strategic pipeline development**
- ✓ **Industry leading management team with extensive experience and expertise in cell therapy**

CONTACT INFORMATION

Jennifer Chow
Chief Executive Officer
Chimeric Therapeutics Ltd
Cell: +1 908-723-8387
jchow@chimerictherapeutics.com

Paul A. Hopper
Executive Chairman
Chimeric Therapeutics Ltd
Cell: +61 406671515
paulhopper@lifescienceportfolio.com